title: Successful treatment of severe juvenile microscopic polyangiitis with rituximab.
abstract: Microscopic polyangiitis (MPA) previously called hypersensitivity angiitis is a systemic necrotizing vasculitis affecting predominantly small vessels. MPA involves multiple organ systems including the lung, the kidneys, the joints, and the skin. MPA mostly affects adults in their fourth and fifth decade of life. MPA and Wegener;s granulomatosis are grouped together as ANCA-associated vasculitis. MPA is associated with high titre of myeloperoxidase antineutrophil cytoplasmic antibodies (MPO)-ANCA. We present a 14-year-old female patient presented with MPA. She was treated with steroids and cyclophosphamide. After the complication of severe lung involvement, rituximab was administered as immune-modulating treatment. The MPA came to remission. This is the first report of a pediatric patient with MPA treated with rituximab. Rituximab might be a potential therapeutic option for relapsing ANCA associated vasculitis in childhood.
authors.affiliation: Department of Paediatrics, Innsbruck Medical University, Anichstrasse 35, Innsbruck 6020, Austria. juergen.brunner@uki.at
authors.forename: J
authors.initials: J
authors.lastname: Brunner
authors.forename: M
authors.initials: M
authors.lastname: Freund
authors.forename: M
authors.initials: M
authors.lastname: Prelog
authors.forename: E
authors.initials: E
authors.lastname: Binder
authors.forename: M
authors.initials: M
authors.lastname: Sailer-Hoeck
authors.forename: T
authors.initials: T
authors.lastname: Jungraithmayr
authors.forename: C
authors.initials: C
authors.lastname: Huemer
authors.forename: C
authors.initials: C
authors.lastname: Sergi
authors.forename: L B
authors.initials: LB
authors.lastname: Zimmerhackl
mesh_terms: D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D005260:Female; D005921:Glomerulonephritis / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D000069283:Rituximab; D018366:Vasculitis, Leukocytoclastic, Cutaneous / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab